Conditions: Hepatic Insufficiency
Keywords: hepatic impairment
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 24
Healthy volunteers: yes

Brief summary:
This study will evaluate the effects of mild and moderate impairment of hepatic function on the single-dose pharmacokinetics, safety and tolerability of AG-013736.

Detailed description:

Arms:
arm 1: Subjects with mild hepatic impairment (Child Pugh class A, score 5-6) arm 2: Subjects with moderate hepatic impairment(Child Pugh class B,score 7-9) arm 3: Group 1

1\) subjects with normal hepatic function

Interventions: intervention 1: AG-013736 intervention 2: AG-013736 intervention 3: AG-013736
Intervention descriptions: intervention 1: Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet. intervention 2: Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet. intervention 3: Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.

Protocol document: